Early last February, Myriad Genetics reported fiscal second quarter posted strong earnings and updated its full-year 2014 guidance to levels above the analyst consensus. Even better, the company announced the acquisition of Crescendo Bioscience, a …
Smallcap Network · 5/5/2014
CDK Global (NASDAQ: CDK) 10.3% HIGHER; said to be working with Morgan Stanley to explore sale, according to Bloomberg. Freshpet (NASDAQ: FRPT) 7.5% LOWER; reported Q2 EPS of ($0.07), $0.02 worse than the analyst estimate of ($0.05) …
StreetInsider · 8/11/2015
Myriad Genetics (NASDAQ:MYGN) had its target price lowered by JMP Securities from $46.00 to $40.00 in a report issued on Wednesday morning, ARN reports. The brokerage currently has a market outperform rating on the stock. Shares of Myriad … · 8/15/2015
Myriad Genetics (MYGN) shares were up more than 11% yesterday to close at a 52-week high of $35.03 yesterday, after the company published data in the Journal of Urology proving that its recurring prostate cancer detection test, Prolaris, yielded positive ... · 2/19/2014
11/06/2013 - Growing Stock Report initiates its NASDAQ Active Stock Watch List adding Myriad Genetics Inc. MYGN, +0.40% NPS Pharmaceuticals, Inc. NPSP Durata Therapeutics, Inc. DRTX and Albany Molecular Research Inc. AMRI, +1.96% Myriad …
Market Watch · 11/7/2013
Rex Energy Corporation (REXX) < traded at $4.44 – 0.56 (11.20 percent). Myriad Genetics Inc. (MYGN) had a gap down today of (1.27) points or -3.33 percent below its previous close of $38.12. Myriad Genetics Inc. (MYGN) < traded at $33.03 – 5.085 (13.
Fx Pips · 2/5/2015
Gene-testing company Myriad Genetics (MYGN) jumped to a five-year high in morning trading in the stock market today after it revealed late Tuesday that the U.S. government is paying a heftier reimbursement for its main test than previously feared.
Investors Business Daily · ByAmy Reeves · 4/2/2014
Investors in Myriad Genetics, Inc. (NASDAQ:MYGN) saw new options begin trading this week, for the September 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MYGN options chain for the new September …
Market News Video · 8/6/2010
Shares closed on Monday at $7.23. The company reports earnings on November 6. Myriad Genetics Inc. (NASDAQ: MYGN) is a biotech stock that has hammered the shorts so far this year, up 75%. The company announced Monday that it has signed an …
24/7 Wall ST · 11/4/2014
This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on MYGN at
CNBC · 8/11/2015